Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$82.3m

Aclaris Therapeutics Future Growth

Future criteria checks 1/6

Aclaris Therapeutics's earnings are forecast to decline at 11.1% per annum while its annual revenue is expected to grow at 12.2% per year. EPS is expected to decline by 1.4% per annum.

Key information

-11.1%

Earnings growth rate

-1.4%

EPS growth rate

Pharmaceuticals earnings growth21.4%
Revenue growth rate12.2%
Future return on equityn/a
Analyst coverage

Good

Last updated04 Mar 2024

Recent future growth updates

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Recent updates

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aug 25
Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow

Jun 08

Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

May 28
Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

Aclaris Therapeutics EPS misses by $0.29, beats on revenue

May 07

Earnings and Revenue Growth Forecasts

NasdaqGS:ACRS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610-134-113-506
12/31/20259-100-105-459
12/31/20248-74-176710
12/31/202331-88-80-78N/A
9/30/202321-115-92-91N/A
6/30/202331-105-75-74N/A
3/31/202331-96-74-73N/A
12/31/202230-87-68-68N/A
9/30/202224-82-66-66N/A
6/30/20226-83-69-68N/A
3/31/20226-81-61-61N/A
12/31/20217-91-52-52N/A
9/30/20217-82-44-44N/A
6/30/20217-71-46-45N/A
3/31/20217-65-44-44N/A
12/31/20206-51-39-39N/A
9/30/20206-57-51-50N/A
6/30/20206-69-63-61N/A
3/31/20204-102-73-72N/A
12/31/20194-114-98-96N/A
9/30/20195-118-105-103N/A
6/30/20195-115-111-110N/A
3/31/20196-79-112-110N/A
12/31/20186-82-102-101N/A
9/30/20185-81-94-92N/A
6/30/20185-79-77-76N/A
3/31/20183-86-65-64N/A
12/31/20172-50-56-55N/A
9/30/20171-57N/A-45N/A
6/30/2017N/A-50N/A-41N/A
3/31/2017N/A-48N/A-40N/A
12/31/2016N/A-48N/A-35N/A
9/30/2016N/A-42N/A-31N/A
6/30/2016N/A-42N/A-31N/A
3/31/2016N/A-33N/A-24N/A
12/31/2015N/A-23N/A-20N/A
9/30/2015N/A-21N/A-19N/A
6/30/2015N/A-13N/A-10N/A
3/31/2015N/A-12N/A-9N/A
12/31/2014N/A-11N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACRS's revenue (12.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ACRS's revenue (12.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACRS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.